Trials / Completed
CompletedNCT02152306
Fimasartan/Amlodipine Combination Phase III
A Randomized, Double-blind Multicenter, Phase III Study to Evaluate the Efficacy and Safety of Combination of Fimasartan/Amlodipine Versus Fimasartan Monotherapy in Patients With Essential Hypertension Who Fail to Respond Adequately to Fimasartan Monotherapy.
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 143 (actual)
- Sponsor
- Boryung Pharmaceutical Co., Ltd · Industry
- Sex
- All
- Age
- 20 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The aim of this study is to ensure the superiority of Fimasartan/Amlodipine combination in hypotensive effect after 8 weeks of treatment over Fimasartan monotherapy in patients with hypertension who have no response to Fimasartan 60mg monotherapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Fimasartan and Amlodipine | |
| DRUG | Fimasartan |
Timeline
- Start date
- 2014-04-01
- Primary completion
- 2015-03-01
- Completion
- 2015-07-01
- First posted
- 2014-06-02
- Last updated
- 2015-07-27
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT02152306. Inclusion in this directory is not an endorsement.